Connect with us

Technology

In HelloNation, Optometry Expert Dr. Spencer Franz Discusses Early Signs of Glaucoma

Published

on

The article explains why regular eye exams and glaucoma testing are important for detecting the disease before significant vision loss occurs.

HOBBS, N.M., Aug. 7, 2026 /PRNewswire/ — What are the early signs of glaucoma, and how can people detect it before permanent vision loss occurs? A HelloNation article featuring Dr. Spencer Franz of The Eye Site in Hobbs, New Mexico, outlines how regular eye exams are the best way to catch this silent condition early.

The article explains that glaucoma is a progressive eye disease that damages the optic nerve and can lead to irreversible vision loss. Many people do not know they have it until the condition has already caused harm. The most common form, open-angle glaucoma, develops gradually and often begins by affecting peripheral vision. Because central vision may remain clear in the early stages, daily tasks can still seem normal even as damage is occurring.

According to the HelloNation feature, glaucoma rarely causes pain or immediate symptoms. Early indicators can be subtle, such as difficulty seeing in dim light or slower adjustment to darkness, but many people experience no warning signs at all. This quiet progression is why glaucoma is often referred to as the silent thief of sight.

Risk factors for glaucoma include age, family history, high eye pressure, diabetes, and previous eye injuries. Adults over 40, especially those with a family history of the disease, are considered at higher risk. Dr. Franz emphasizes that even individuals without obvious risk factors can develop glaucoma, which makes routine glaucoma testing essential.

The article highlights how regular eye exams allow eye care professionals to check for signs of glaucoma before symptoms become noticeable. These exams include measurements of eye pressure and a detailed examination of the optic nerve. Additional glaucoma testing may involve checking peripheral vision and capturing images of the eye’s internal structure. When tracked over time, these exams can help identify early changes and guide treatment decisions.

In Hobbs, regular eye exams provide a critical opportunity for early detection. Many adults only seek care when they experience blurry vision, but glaucoma often advances without affecting clarity in the beginning. Dr. Franz encourages patients to view eye exams not just as a response to vision problems, but as a way to protect long-term eye health.

Once diagnosed, glaucoma cannot be cured or reversed, but early treatment can prevent further vision loss. Treatment often begins with prescription eye drops that lower eye pressure. In more advanced cases, laser procedures or surgery may be necessary. The HelloNation article stresses that the goal of treatment is to prevent additional damage, not to recover what has been lost.

Consistent monitoring is a key part of managing glaucoma. Because eye pressure and optic nerve health can change over time, skipping medications or appointments can lead to worsening conditions. Dr. Franz explains that successful long-term management depends on regular checkups and a commitment to the care plan.

Even minor vision loss from glaucoma can have a major impact. Losing peripheral vision may affect driving safety, mobility, and independence. Tasks like reading or navigating busy spaces can become more difficult. Early diagnosis and proper management support a better quality of life by helping individuals maintain their daily routines and independence.

Understanding the signs and risks of glaucoma helps people take an active role in protecting their vision. Regular eye exams offer a safe and effective way to detect glaucoma early. For adults in Hobbs and surrounding communities, taking action before symptoms appear is the best way to reduce the risk of serious vision loss.

What Are the Early Signs of Glaucoma? How to Catch Vision Loss Before It’s Too Late features insights from Dr. Spencer Franz, Optometry Expert of Hobbs, NM, in HelloNation.

About HelloNation
HelloNation is America’s Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative “edvertising” approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities.

View original content to download multimedia:https://www.prnewswire.com/news-releases/in-hellonation-optometry-expert-dr-spencer-franz-discusses-early-signs-of-glaucoma-302846160.html

SOURCE HelloNation

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Cosign Launches in San Jose as Silicon Valley Rental Competition Hits a Decade High

Published

on

By

The Platform Offers a Cosigner Alternative Amid Tightening Vacancy

SAN JOSE, Calif., Aug. 7, 2026 /PRNewswire/ — Cosign, a cosigner and third-party lease guarantor platform designed to expand renter access while protecting property owners, has launched in San Jose, the heart of Silicon Valley, where rental competition has reached levels not seen in more than a decade.

According to CoStar data, average rent in San Jose is up roughly 7% in the last year, meaning income requirements are rising far faster than most renters’ paychecks. Average asking rent currently sits around $3,432 a month, behind only New York and San Francisco. Renters with steady income and years of local employment, teachers, service workers and contractors among them, are getting stuck at the apartment approval stage simply because they don’t have a cosigner to fall back on. The issue isn’t a lack of qualified renters. It’s approval standards that require applicants to clear roughly a $124,000 annual income threshold or provide a cosigner.

At Vasona Management, that squeeze has become a daily leasing challenge. Management adopted Cosign as a cosigner alternative to solve exactly that problem. As a San Jose apartment guarantor, Cosign steps in when renters fall just short of standard qualification criteria and have no cosigner to rely on, allowing Vasona’s properties to approve more residents, reduce vacancy rate and maintain financial protections.

“At Vasona Management, providing a seamless leasing experience while maintaining strong qualification standards is a top priority,” said Samantha Woehl, director of training and management at Vasona Management. “Cosign, as a third-party guarantor, has given us greater flexibility when working with applicants who fall just short of our traditional screening criteria and don’t have a cosigner. It allows us to confidently approve more qualified residents while keeping the leasing process efficient for both our team and our communities.”

Founded by real estate owners and operators, Cosign’s dynamic risk model evaluates payment behavior and recency rather than relying on a credit score alone, an approach that gives the San Jose MSA’s non-tech workforce, the people who keep the region running but don’t carry tech salaries, a real path to apartment approval.

“This market shows what happens when a decade of undersupply finally catches up with a market,” said Zach Schofel, co-founder and CEO of Cosign. “Cosign works with thousands of units in the MSA and over 30,000 units across the state, and we’re excited to expand our presence in the area. Reception from local managers and residents has been amazing. The renters getting left behind aren’t the ones who can’t afford it. They’re the ones without a backup plan on paper. Cosign gives owners in Silicon Valley a way to say yes to them anyway.”

For more information, visit www.rentwithcosign.com and follow on social media @rentwithcosign.

About Cosign
Cosign is a real estate technology company and lease guarantor service that bridges the gap between qualified renters and landlords. Founded by real estate professionals, Cosign’s mission is to expand housing access through data-driven underwriting that considers payment behavior, not just credit scores. Active in more than 500,000 units across 3,000+ communities nationwide, Cosign is helping modern operators approve more qualified renters in both tight and oversupplied markets. For more information, visit www.rentwithcosign.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cosign-launches-in-san-jose-as-silicon-valley-rental-competition-hits-a-decade-high-302846247.html

SOURCE Cosign

Continue Reading

Technology

bioMérieux Highlights Positive Impacts of Rapid, Accurate Diagnostics for Patients and Accepts Industry Awards at ADLM 2026

Published

on

By

SALT LAKE CITY, Aug. 7, 2026 /PRNewswire/ — bioMérieux, a world leader in the field of in vitro diagnostics, leveraged this year’s 2026 Association for Diagnostics & Laboratory Medicine (ADLM) Annual Conference & Clinical Lab Expo for an important conversation about the impact of access to diagnostics while also accepting multiple IMV ServiceTrak™ awards.

PRESS CONFERENCE
The company hosted a press panel, The Power of Diagnostics: How Delays Impact Patients and Providers, to discuss the real-world impacts of delayed or inaccurate diagnostic answers for patients, providers, communities, and the healthcare system. Dr. Charles K. Cooper, Executive Vice President and Chief Medical Officer at bioMérieux, moderated the panel with:

Dr. Omai Garner, Clinical Professor and Director of Clinical Microbiology, UCLA;Dr. Michael Astion, PhD, Medical Director, Regional Laboratories and Point of Care, Medical Director, Reference Laboratories and PLUGS (Patient-Centered Laboratory Utilization Guidance Services), Department of Laboratories, Seattle Children’s Hospital, Professor of Laboratory Medicine and Pathology, University of Washington;Helaine Bader, MPH Vice President of Education, HealthyWomen; andDr. John Hurst, Senior Director, Field Medical Affairs at bioMérieux.

Dr. Cooper noted that the panel discussed the “tremendous amount of pressure health care systems face and how access to rapid diagnostics at the point of care often alleviates some of this stress by getting health care clinicians and their patients answers while they wait.”

“Delay in getting a diagnosis may result in patients not receiving treatment at all because they may not come back for follow-up,” said Ms. Bader. “Faster time to diagnosis during a single visit not only provides the patient with immediate answers but also builds trust between the patient and provider and reduces patient frustration, potential complications from the infection and the need for repeat visits.”

INDUSTRY RECOGNITION
During the show, bioMérieux also accepted seven 2026 IMV ServiceTrak™ Clinical Laboratory Awards. These awards highlight bioMérieux’s continued commitment to delivering industry-leading diagnostic solutions and exceptional customer support to clinical laboratories.

2026 ServiceTrak Awards: ID/AST Systems

Best Customer SatisfactionBest System PerformanceBest Service

2026 ServiceTrak Awards: Blood Culture Systems

Best Customer SatisfactionBest System PerformanceBest Service

2026 Best System Performance

Immunoassay Analyzers

“We are thrilled that IMV and the Science and Medicine Group has recognized bioMérieux for the ninth consecutive year for the continued dedication and excellence of our product management, operations, and customer support teams,” said Randy Pritchard, General Manager and Sr. Vice President of Clinical Operations, bioMérieux. “This recognition, across our immunoassay, ID/AST Systems, and Blood Culture Systems offerings, highlights our commitment to pioneering diagnostics in the fight against sepsis and antimicrobial resistance.”

ABOUT BIOMÉRIEUX
Pioneering Diagnostics

A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 46 countries and serves more than 160 countries with the support of a large network of distributors. In 2025, revenues reached €4.1 billion, with over 94% of sales outside of France.

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
www.biomerieux.com.

bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP

View original content to download multimedia:https://www.prnewswire.com/news-releases/biomerieux-highlights-positive-impacts-of-rapid-accurate-diagnostics-for-patients-and-accepts-industry-awards-at-adlm-2026-302846267.html

SOURCE bioMérieux

Continue Reading

Technology

CNO Financial Group to Host Virtual Investor Briefing on Tuesday, September 1, 2026

Published

on

By

CARMEL, Ind., Aug. 7, 2026 /PRNewswire/ — CNO Financial Group, Inc. (NYSE: CNO) today announced it will host a virtual investor briefing focused on its Worksite Division and Medicare business on Tuesday, September 1, 2026, from 10:00 a.m. to approximately 11:15 a.m. Eastern Time.

The briefing will feature presentations on market opportunities, growth strategies and business fundamentals, along with interactive Q&A sessions with Worksite Division President Karen DeToro, Consumer Division President Scott Goldberg, Chief Actuary Jeremy Williams and other members of senior management.

CNO is committed to engaging with investors and other stakeholders to deepen their understanding of our business, strategy and long-term opportunities. This briefing represents the third installment in our investor briefing series, with prior sessions covering the Consumer Division and Investments function, which are available here.

Participate by Webcast
To participate, please register here. The event will also be accessible through the Investors section of our website at ir.CNOinc.com. Participants should register on the website at least 15 minutes before the event begins.

Participate by Replay
A replay of the webcast will be available on the Investors section of our website at ir.CNOinc.com.

About CNO Financial Group
CNO Financial Group, Inc. (NYSE: CNO) secures the future of middle-income America. CNO provides life and health insurance, annuities and financial services through our family of brands, including Bankers Life, Colonial Penn, Optavise and Washington National. Our customers work hard to save for the future, and we help protect their health, income and retirement needs with 3.3 million policies and $39.9 billion in total assets. Our 3,200 associates, 5,100 exclusive agents and more than 6,500 independent partner agents guide individuals, families and businesses through a lifetime of financial decisions. For more information, visit CNOinc.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cno-financial-group-to-host-virtual-investor-briefing-on-tuesday-september-1-2026-302846212.html

SOURCE CNO Financial Group

Continue Reading

Trending